Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma
Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
After the local treatment of the primary tumor (protonbeam-therapy, enucleation, external
radiotherapy) patients with high risk of metastasis are randomized between:
- Adjuvant chemotherapy with Fotemustin.
- Observation
Both groups are followed during 3 years for Metastasis- Free Survival, safety and tolerance
of Fotemustin, quality of life, and Overall Survival.